BioSpace News Archive

New agreement further expands manufacturing capacity for orally-administered opaganib following positive top-line data from its Phase 2 COVID-19 study, progress with the ongoing global Phase 2/3 study, and amid the urgent need to address emerging viral strains [28-January-2021] TEL AVIV, Israel and RALEIGH, N.C. , Jan. 28, 2021 /PRNewswire/ -- RedHill Biopharma L

Jan. 28, 2021 12:27 UTC OSLO, Norway--( BUSINESS WIRE )-- Ultimovacs ASA (“Ultimovacs”, ticker ULTI), today announced that the lead investigator of the Company’s NIPU Phase II clinical trial, Åslaug Helland from Oslo University Hospital, has presented a poster with an overview of the NIPU trial at the 2020 World Conference on Lung Cancer in Singapore. For more information on the NIPU trial and the poster that was presented today, please refer to Ultimovacs corporate website.

Molluscum contagiosum is a skin infection caused by a poxvirus (molluscum contagiosum virus), which is usually benign. Appearance of lesions anywhere on the body is a characteristic of mild skin disease.

Outsourcing is emerging as a cost-effective tool for healthcare payers. Therefore, the growing trend of outsourcing is working in favor of the global healthcare payer services market.

Evotec SE announced that EVT894, a monoclonal antibody to treat and potentially prevent chikungunya virus infections, has entered clinical development.

Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: “Facilitating extinction of fear with psilocybin:

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Mark Lepore, MD, as the Chief Medical Officer for Allergy.

IDEXX Laboratories, Inc., a global leader in veterinary diagnostics and software, announced a landmark initiative with the Tuskegee University College of Veterinary Medicine, which it intends to support by a contribution of $3.6 million over six years from the IDEXX Foundation, a donor-advised fund administered by a national donor-advised fund program.

- PRV-3279 Murine Surrogate Inhibited the Production of Anti-adenoviral Vector Antibodies in a Mouse Model for Pompe Disease - - Rapid, Robust and Reversible B cell Inhibition Suggest PRV-3279 Could Become an Adjunctive Co-Treatment with Gene Therapy -